Literature DB >> 29758951

SSRI and SNRI withdrawal symptoms reported on an internet forum.

Tom Stockmann1, Dolapo Odegbaro2, Sami Timimi3, Joanna Moncrieff4.   

Abstract

BACKGROUND: Antidepressant withdrawal symptoms are well-recognised, but their potential duration remains uncertain.
OBJECTIVE: We aimed to describe the characteristics of withdrawal associated with two popular classes of antidepressants, including duration.
METHODS: We analysed the content of a sample of posts on an antidepressant withdrawal website. We compared the characteristics of withdrawal associated with SSRIs and SNRIs, including time of onset, duration and nature of symptoms.
RESULTS: 110 posts about SSRI withdrawal, and 63 concerning SNRI withdrawal, were analysed. The mean duration of withdrawal symptoms was significantly longer with SSRIs than SNRIs: 90.5 weeks (standard deviation, SD, 150.0) and 50.8 weeks (SD 76.0) respectively; p = 0.043). Neurological symptoms, such as 'brain zaps,' were more common among SNRI users (p = 0.023). Psychosexual/genitourinary symptoms may be more common among SSRI users (p = 0.054). LIMITATIONS: The website aims to help people with antidepressant withdrawal, and is therefore likely to attract people who have difficulties. Length of prior use of antidepressants was long, with a mean of 252.2 weeks (SD 250.8).
CONCLUSIONS: People accessing antidepressant withdrawal websites report experiencing protracted withdrawal symptoms. There are some differences in the characteristics of withdrawal associated with different classes of antidepressants.

Entities:  

Keywords:  Antidepressant; SNRI; SSRI; antidepressant withdrawal; online report

Mesh:

Substances:

Year:  2018        PMID: 29758951     DOI: 10.3233/JRS-180018

Source DB:  PubMed          Journal:  Int J Risk Saf Med        ISSN: 0924-6479


  8 in total

1.  The 'patient voice': patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition.

Authors:  Anne Guy; Marion Brown; Stevie Lewis; Mark Horowitz
Journal:  Ther Adv Psychopharmacol       Date:  2020-11-09

2.  A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.

Authors:  Mark Abie Horowitz; Sameer Jauhar; Sridhar Natesan; Robin M Murray; David Taylor
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 7.348

3.  What it was like to stop an antidepressant.

Authors:  Tom Stockmann
Journal:  Ther Adv Psychopharmacol       Date:  2019-11-01

Review 4.  How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding.

Authors:  Michael P Hengartner
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-08

5.  The role of Facebook groups in the management and raising of awareness of antidepressant withdrawal: is social media filling the void left by health services?

Authors:  Edward White; John Read; Sherry Julo
Journal:  Ther Adv Psychopharmacol       Date:  2021-01-17

6.  Antidepressant withdrawal - the tide is finally turning.

Authors:  Michael P Hengartner; James Davies; John Read
Journal:  Epidemiol Psychiatr Sci       Date:  2019-08-22       Impact factor: 6.892

7.  Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum.

Authors:  Michael P Hengartner; Lukas Schulthess; Anders Sorensen; Adele Framer
Journal:  Ther Adv Psychopharmacol       Date:  2020-12-24

8.  Integrated transcriptomic and metabolomic analysis of rat serum to investigate potential target of puerarin in the treatment post-traumatic stress disorder.

Authors:  Aishan Su; Xiaoyun Chen; Zijing Zhang; Bo Xu; Chaoqun Wang; Zhongyuan Xu
Journal:  Ann Transl Med       Date:  2021-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.